We are standing at the threshold of the biggest business opportunity in a century. Despite conventional wisdom that adding 2.5 billion people to the planet will result in stagnating economic growth, ...

Changing the FDA biosimilar interchangeability standards is a necessary but likely insufficient step to improve biosimilar competition in the US. In 2009, Congress created a regulatory pathway for ...